Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases.
Document Type
Article
Publication Date
8-1-2017
Abstract
BACKGROUND: The Metastatic colorectal cancer liver metastases Outcomes after RadioEmbolization (MORE) study was a retrospective analysis of 606 patients with unresectable colorectal liver metastases treated with radioembolization (RE) using
METHODS:
RESULTS: Dates of death were obtained for 574 out of a total of 606 patients, and overall survival (OS) data analyzed. Updated median OS was 10.0 months (95% CI: 9.2-11.8 months) at a median follow-up of 9.5 months versus the originally reported median OS of 9.6 months (95% CI: 9.0-11.1 months) at a follow-up of 8.6 months in the first MORE analysis. Patients received a median (range) of 2 (0 to 6) lines of chemotherapy. Baseline characteristics and factors significantly associated with patient survival (P
CONCLUSIONS: Long-term follow-up confirms that
Volume
8
Issue
4
First Page
614
Last Page
624
Recommended Citation
Kennedy A, Cohn M, Coldwell DM, Drooz A, Ehrenwald E, Kaiser A, Nutting CW, Rose SC, Wang EA, Savin MA. Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases. J Gastrointest Oncol. 2017 Aug;8(4):614-624. doi: 10.21037/jgo.2017.03.10. PubMed PMID: 28890810; PubMed Central PMCID: PMC5582033.
DOI
10.21037/jgo.2017.03.10
ISSN
2078-6891
PubMed ID
28890810